SAN DIEGO, Oct. 1, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
diagnostic assays, products and services designed to provide
physicians with clinically actionable information to improve
patient outcomes, announces the upcoming presentation of results
from a prospective study using its Target Selector™ testing of the
cerebrospinal fluid in patients with non-small lung cancer (NSCLC). The
study results will be discussed in a poster presentation at the
International Association for the Study of Lung Cancer (IASLC)
Virtual Lung Cancer Hot Topic Meeting: Liquid Biopsy by
David Berz, MD, PhD, MPH of the
Beverly Hills Cancer Center, on October
2 from 2:30-3:30 p.m. Eastern
time.
Central nervous system involvement by metastasis occurs in 3% to
4% of patients with NSCLC and 9% of NSCLC patients with EGFR
mutations. Involvement of the lepto-meninges, thin membranous
connective tissue layers with blood vessels that surround the brain
and spinal cord, accounts for deteriorating neurologic function,
mental status changes and poor prognosis in these patients, but can
be difficult to diagnose with current methods.
This prospective study evaluated results from Biocept's combined
circulating tumor cell (CTC) and circulating tumor DNA (ctDNA)
liquid biopsy testing compared to conventional cytology
examination, the current standard-of-care, for confirming the
diagnosis of leptomeningeal metastases in patients with
EGFR-mutated NSCLC undergoing treatment with Tesevatinib, an
experimental EGFR tyrosine kinase inhibitor (NCT02616393).
"Testing the cerebrospinal fluid of patients for metastases to
the central nervous system is a key component of our oncology
testing business," said Michael
Nall, President and CEO of Biocept. "We are excited
that Dr. Berz, a national thought leader in lung malignancies and
personalized oncology treatment, will present these results at the
IASLC conference which features the latest developments in cancer
treatment including liquid biopsy clinical utility."
About the IASLC 2020 Lung Cancer Hot Topic Meeting: Liquid
Biopsy
There have been numerous advances in liquid biopsy since this
event's advent in 2018, and the concept of a "blood-first"
approach—superseding or replacing tissue biopsy—is a current topic
of much debate and discussion. This innovative virtual
conference will bring together international and multidisciplinary
experts in the field of liquid biopsy in lung cancer to present and
discuss current technology and best practices for clinical
applications based on available data.
About the IASLC
The International Association for the Study of Lung Cancer
(IASLC) is the only global organization dedicated solely to the
study of lung cancer and other thoracic malignancies. Founded in
1974, the association's membership includes nearly 9,000 lung
cancer specialists across all disciplines in over 100 countries,
forming a global network working together to conquer lung and
thoracic cancers worldwide. The association also publishes
the Journal of Thoracic Oncology, the primary educational and
informational publication for topics relevant to the prevention,
detection, diagnosis and treatment of all thoracic malignancies.
Please visit www.iaslc.org for more
information.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with clinically
actionable information for treating and monitoring patients
diagnosed with cancer. The Company's patented Target Selector™
liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. In
addition, Biocept recently added COVID-19 testing to support
efforts to fight the pandemic. For additional information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements regarding the ability of our tests to
provide clinically actionable information and the ability of
Biocept's platform to identify cancer mutations and alterations to
inform physicians about a patient's disease and therapeutic
options, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our Securities
and Exchange Commission (SEC) filings. The effects of such risks
and uncertainties could cause actual results to differ materially
from the forward-looking statements contained in this release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC, which can be accessed over the
Internet at the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-to-present-study-results-from-target-selector-testing-in-the-cerebrospinal-fluid-of-patients-with-lung-cancer-at-the-iaslc-liquid-biopsy-meeting-301143765.html
SOURCE Biocept, Inc.